The inhibitory co-receptors: A way to save from anergy the HIV-specific T cells

Current HIV Research

Volumn 7, Issue 3, 2009, Pages 266-272

  Simone, Rita ^a,b   Piatti, Gabriella ^a   Saverino, Daniele ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

CTLA 4; Exhausted T cells; HIV; PD 1

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 PROTEIN; PROGRAMMED DEATH LIGAND 1; PROGRAMMED DEATH LIGAND 2; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; LEUKOCYTE ANTIGEN; PDCD1 PROTEIN, HUMAN;

CD4+ T LYMPHOCYTE; CELL EXPANSION; CLONAL ANERGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE DYSREGULATION; IMMUNOREGULATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; VIROLOGY;

ANTIGENS, CD; APOPTOSIS REGULATORY PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS;

EID: 67649099437     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016209788347949     Document Type: Review

References (62)

1. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005; 23: 515-48.
2. Flies DB, Chen L. The new B7s: playing a pivotal role in tumor immunity. J Immunother 2007; 30: 251-60.
3. Ling V, Wu PW, Spaulding V, et al. Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss. Genomics 2003; 82: 365-77.
4. Borriello F, Freeman GJ, Edelhoff S, et al. Characterization of the murine B7-1 genomic locus reveals an additional exon encoding an alternative cytoplasmic domain and a chromosomal location of chromosome 16, band B5. J Immunol 1994, 153: 5038-5048.
5. Borriello F, Oliveros J, Freeman GJ, et al. Differential expression of alternate mB7-2 transcripts. J Immunol 1995; 155: 5490-7.
6. Guo Y, Wu Y, Zhao M, et al. Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain. J Exp Med 1995; 181: 1345-55.
7. Ling V, Wu PW, Miyashiro JS, et al. Differential expression of inducible costimulator-ligand splice variants: lymphoid regulation of mouse GL50-b and human GL50 molecules. J Immunol 2001; 166: 7300-8.
8. He XH, Liu Y, Xu LH, Zeng YY. Cloning and identification of two novel splice variants of human PD-L2. Acta Biochim Biophys Sin 2004; 36: 284-9.
9. Prasad DVR, Richards S, Mai XM, Dong C. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 2003; 18: 863-73.
10. Sica GL, Choi IH, Zhu G, et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 2003; 18: 849-61.
11. Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune response. Annu Rev Immunol 2002; 20: 29-53.
12. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001; 1: 220-8.
13. Lee KM, Chuang E, Griffin M, et al. Molecular basis of T cell inactivation by CTLA-4. Science 1998; 282: 2263-6.
14. Marengere LE, Waterhouse P, Duncan GS, et al. Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science 1996; 272: 1170-3.
15. Chuang E, Fisher TS, Morgan RW, et al. The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A. Immunity 2000; 13: 313-22.
16. Hu H, Rudd CE, Schneider H. Src kinases Fyn and Lck facilitate the accumulation of phosphorylated CTLA-4 and its association with PI-3 kinase in intracellular compartments of T-cells. Biochem Biophys Res Commun 2001; 288: 573-8.
17. Brunner MC, Chambers CA, Chan FK, et al. CTLA-4-mediated inhibition of early events of T cell proliferation. J Immunol 1999; 162: 5813-20.
18. Greenwald RJ, Oosterwegel MA, van Der Woude D, et al. CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol 2002; 32: 366-73.
19. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001; 19: 565-94.
20. Egen JG, Allison JP. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 2002; 16: 23-35.
21. Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3: 541-7.
22. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995; 270: 985-8.
23. Chambers CA, Sullivan TJ, Allison JP. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity 1997; 7: 885-95.
24. Perez VL, Van Parijs L, Biuckians A, et al. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 1997; 6: 411-7.
25. Greenwald RJ, Boussiotis VA, Lorsbach RB, et al. CTLA-4 regulates induction of anergy in vivo. Immunity 2001; 14: 145-55.
26. Appleman LJ, Berezovskaya A, Grass I, Boussiotis VA. CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression. J Immunol 2000; 164: 144-51.
27. Boussiotis VA, Freeman GJ, Taylor PA, et al. p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat Med 2000; 6: 290-7.
28. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996; 183: 2533-2540.
29. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996; 183: 2541-50.
30. Bachmann MF, Kohler G, Ecabert B, et al. Lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J Immunol 1999; 163: 1128-31.
31. Bachmann MF, Gallimore A, Jones E, Ecabert B, Acha-Orbea H, Kopf M. Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: a paradigm reconsidered. Eur J Immunol 2001; 31: 450-8.
32. Day CL, Walker BD. Progress in defining CD4 helper cell responses in chronic viral infections. J Exp Med 2003; 198(12): 1773-7.
33. Mohamed El-Far, Rabih Halwani, Elias Said, et al. T-cell exhaustion in HIV infection. Current HIV/AIDS 2008; 5: 13-9.
34. Hryniewicz A, Boasso A, Edghill-Smith Y, et al. CTLA-4 blockade decreases TGF-b, indoleamine 2,3-dioxygenase and viral RNA expression in tissues of SIVmac251-infected macaques. Blood 2006; 108: 3834-42.
35. Kaufmann DE, Kavanagh DG, Pereyra F, et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 2007; 8: 1246-54.
36. Zaunders JJ, Ip S, Munier ML, et al. Infection of CD127+ (interleukin-7 receptor +)CD4 + cells and overexpression of CTLA-4 are linked to loss of antigen-specific CD4 T cells during primary human immunodeficiency virus type 1 infection. J Virol 2006; 80: 10162-72.
37. Thio CL, Mosbruger TL, Kaslow RA, et al. Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection. J Virol 2004; 78: 11258-62.
38. Leng Q, Bentwich Z, Magen E, et al. CTLA-4 upregulation during HIV infection: association with anergy and possible target for therapeutic intervention. AIDS 2002; 16: 519-29.
39. Leng Q, Borkow G, Bentwich Z. Attenuated signaling associated with immune activation in HIV-1-infected individuals. Biochem Biophys Res Commun 2002; 298: 464-7.
40. Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996; 8: 765-72.
41. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-34.
42. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and Its Ligands in Tolerance and Immunity. Annual Rev Immunol 2008; 26: 677-704.
43. Olive D. Lymphocyte coreceptors. Med Sci 2006; 22: 1069-74.
44. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2: 261-8.
45. Brown JA, Dorfman DM, Ma FR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003; 170: 1257-66.
46. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439: 682-7.
47. Kaufmann DE, Walker BD. Programmed death-1 as a factor in immune exhaustion and activation in HIV infection. Curr Opin HIV AIDS 2008; 3: 362-7.
48. Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8 + T cells leads to reversible immune dysfunction. Nat Med 2006; 12: 1198-202.
49. Petrovas C, Casazza JP, Brenchley JM, et al. PD-1 is a regulator of virus-specific CD8 + T cell survival in HIV infection. J Exp Med 2006; 203: 2281-92.
50. Rowland-Jones S, de Silva T. Resisting immune exhaustion in HIV-1 infection. PLoS Med 2008; 5: e103.
51. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443: 350-4.
52. Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med 2006; 203: 2223-7.
53. Yao S, Chen L. Reviving exhausted T lymphocytes during chronic virus infection by B7-H1 blockade. Trends Mol Med 2006; 12: 244-6.
54. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006; 27: 195-201.
55. Okazaki T, Wang J. PD-1/PD-L pathway and autoimmunity. Autoimmunity 2005; 38: 353-7.
56. Blattman JN, Greenberg PD. PD-1 blockade: rescue from a near-death experience. Nat Immunol 2006; 7: 227-78.
57. Rowland-Jones S, Dong T. HIV: Tired T cells turn around. Nature 2006; 443: 282-3.
58. Alison Farrell. Defeating T-cell fatigue in HIV. Nat Med 2006; 12: 1124-5.
59. Petrovas C, Mueller YM, Katsikis PD. Apoptosis of HIV-specific CD8+ T cells: an HIV evasion strategy. Cell Death Differ 2005; 1: 859-70.
60. Petrovas C, Casazza JP, Brenchley JM, et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006; 203: 2281-92.
61. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T cell exhaustion and disease progression. Nature 2006; 443: 350-54.
62. Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006; 12: 1198-202.